Liu JF, Herold C, Gray KP, et al. - Researchers undertook this single-arm, phase 2 study in women with relapsed ovarian cancer, to assess the activity of combined nivolumab and bevacizumab in these patients enrolled at 2 sites in the United States. Participants (n = 38) were having relapsed epithelial ovarian cancer and suffered disease recurrence within 12 months of their last platinum-based therapy and had received between 1 and 3 lines of previous therapy. These patients were administered intravenous nivolumab and intravenous bevacizumab once every 2 weeks. Objective response rate, assessed by Response Evaluation Criteria in Solid Tumors 1.1, was the primary endpoint. Following the receipt of this combination therapy, an objective confirmed response by Response Evaluation Criteria in Solid Tumors 1.1 was achieved in 28.9%, meeting the threshold for additional investigation of the combination in this setting. In platinum-sensitive patients and in platinum-resistant patients, the response rate was estimated to be 40.0% and 16.7%, respectively. Overall, the activity of nivolumab with bevacizumab combination was shown in patients with relapsed ovarian cancer. Platinum-resistant settings may require alternative combinational strategies.